Ajinomoto Co., Inc. agrees to acquire Althea Technologies, Inc., a U.S.-based biopharmaceutical Contract Development and Manufacturing Organization (CDMO) for approx. USD 175 million

Ajinomoto announced today that it has executed a merger agreement to acquire all of the capital stock of Althea Technologies, Inc.  a leading biopharmaceutical CDMO, for approximately USD 175 million (approx. JPY 16 billion). Through this acquisition of Althea Technologies Ajinomoto Co. aims to strengthen its business foundation and expand in the rapidly growing advanced biopharma field. Ajinomoto Co. aspires, including this acquisition, to achieve revenue of JPY 30 billion by 2020.

Transaction Valuation

The transaction values Althea at 3.5 times revenue. In 2012, Althea generated $53million in annual revenues. Althea has about 220 employees

About Athea Technologies

Althea Technologies, located in San Diego, CA, is a contract development and manufacturing organization that specializes in cGMP manufacturing, analytical development, aseptic filling into vials & syringes, and protein delivery technology for recombinant protein and parenteral products.  In a single location, Althea has the capacity to meet your early-stage and commercial requirements.
Key Services:

• Cell Line Development
• Process Development
• cGMP Protein & DNA Plasmid Production
• Analytical Method Development
• Lyophilization Cycle Development
• Sterile Vial Filling
• Sterile Syringe Filling

Protein Formulation Technology - Crystalomics™

• High Concentration Formulations
• Sustained Release Formulations
• Proven Technology
• Proven cGMP Manufacturability at Scale

Since its founding in 1998, Althea's manufacturing facilities have been inspected by the FDA in 2005, 2008, 2011, & 2012, and by over 27 different QPs.  To-date, Althea’s cGMP facilities have produced >250 cell banks, >150 cGMP protein & plasmid DNA lots, and >1,300 cGMP fill & finish lots.  Althea has the experience, expertise, capacity, and flexibility to serve as your strategic partner for your drug development and manufacturing needs.